Connect your AI

IDEAYA Biosciences, Inc. IDYA Price / book

Price / book at other companies

Bristol-Myers SquibbBMY

6.2×-1.0×

AmgenAMGN

20.6×-6.3×

Tango TherapeuticsTNGX

7.6×+6.7×

Arcus BiosciencesRCUS

5.2×+3.6×

Erasca, Inc.ERAS

12.8×+11.8×

ImmunomeIMNM

4.2×+2.3×

Other financials

Income statement

Revenue$6.6M—

Operating income-$108.5M-28.6%

Net income-$98.5M-36.5%

EPS (diluted)-$1.11-35.4%

Balance sheet

Cash & equivalents$157.5M+21.2%

Total debt$28.6M+10.1%

Total equity$937.3M-8.5%

Total assets$1.0B-6.4%

Cash flow

Operating cash flow-$75.2M-24.6%

CapEx$967.0K-27.3%

Free cash flow-$76.1M-23.5%

Valuation

Market cap$3.36B+104%

Enterprise value$3.23B+110%

P/S14.5×+9.9×

Profitability

Operating margin-4,671.1%-5,434pp

Net margin-3,921.1%-4,562pp

FCF margin-3,592%-4,290pp

Returns & leverage

Return on equity-14.3%-5.0pp

Debt / equity0×0.0×

Current ratio10.7×-3.2×

Where this comes from

Calculated from IDEAYA Biosciences, Inc.’s reported figures.

market cap/total stockholders equity=3.1×

Based on the most recent quarter.

The official record: IDEAYA Biosciences, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about IDEAYA Biosciences, Inc.'s price / book.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is IDEAYA Biosciences, Inc.'s price / book?: IDEAYA Biosciences, Inc. (IDYA) reported price / book of 3.1× in Q1 2026.
How has IDEAYA Biosciences, Inc.'s price / book changed year-over-year?: IDEAYA Biosciences, Inc.'s price / book increased by 123.0% year-over-year, from 1.4× to 3.1×.
What is the long-term trend for IDEAYA Biosciences, Inc.'s price / book?: Over 5 years (2020 to 2025), IDEAYA Biosciences, Inc.'s price / book has grown at a 1.7% compound annual growth rate (CAGR), from 2.7× to 3×.
What does price / book mean?: Market capitalization at the quarter end divided by shareholders' equity. The premium (or discount) the market assigns to the company's book equity.